The Respiratory Drugs Market growth continues to accelerate as the triple therapy revolution in chronic obstructive pulmonary disease establishes inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta-agonist combinations as the standard of care for symptomatic patients. With COPD affecting over 380 million people globally and remaining a leading cause of morbidity and...